99922-32-4

Basic information

• Product Name: 1H-Benzimidazole,4,7-dimethoxy-2-methyl-(9CI)
• Synonyms: 1H-Benzimidazole,4,7-dimethoxy-2-methyl-(9CI)
• CAS NO: 99922-32-4
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21448
• Product Categories: BENZIMIDAZOLE
• Mol File: 99922-32-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole,4,7-dimethoxy-2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,4,7-dimethoxy-2-methyl-(9CI)(99922-32-4)
• EPA Substance Registry System: 1H-Benzimidazole,4,7-dimethoxy-2-methyl-(9CI)(99922-32-4)

Safety Data

• Hazardous Substances Data: 99922-32-4(Hazardous Substances Data)

Usage

Class

Benzimidazoles (heterocyclic organic compounds with a benzene ring fused to an imidazole ring)

Structure

Two methoxy groups and one methyl group attached to the benzimidazole ring

Usage

Building block for the synthesis of various organic compounds in research and laboratory settings

Value

Unique structure and properties for studying reactivity and behavior of benzimidazole derivatives

Potential

Biological activities and pharmacological properties of interest for further exploration and investigation.

Upstream product

• 40328-95-8 2,3-diamino-1,4-dimethoxybenzene 
• 64-19-7 acetic acid 
• 7767-55-7 2,3-Diamino-1,4-dimethoxybenzene dihydrochloride 
• 150-78-7 1,4-dimethoxybezene 
• 6945-76-2 1,4-dimethoxy-2,3-dinitrobenzene 

Downstream Products

• 797758-51-1 1-benzyl-4,7-dimethoxy-2-methyl-1H-benzoimidazole 

Relevant articles and documents

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

P2X3 receptors (P2X3R) are ATP-gated ion channels predominantly expressed in C-and Aδ-fiber primary afferent neurons and have been introduced as a novel therapeutic target for neurological disorders, including neuropathic pain and chronic cough. Because of its localized distribution, antagonism of P2X3R has been thoroughly considered, and the avoidance of issues related to CNS side effects has been proven in clinical trials. In this article, benzimidazole-4,7-dione-based derivatives were introduced as a new chemical entity for the development of P2X3R antagonists. Starting from the discovery of a hit compound from the screening of 8364 random library compounds in the Korea Chemical Bank, which had an IC50 value of 1030 nM, studies of structure–activity and structure–property relationships enabled further optimization toward improving the antagonistic activities as well as the drug’s physicochemical properties, including metabolic stability. As for the results, the final optimized compound 14h was developed with an IC50 value of 375 nM at P2X3R with more than 23-fold selectivity versus P2X2/3R, along with properties of metabolic stability and improved solubility. In neuropathic pain animal models evoked by either nerve ligation or chemotherapeutics in male Sprague-Dawley rats, compound 14h showed anti-nociceptive effects through an increase in the mechanical withdrawal threshold as measured by von Frey filament following intravenous administration.

Benzimidazole-4,7-diones as inhibitors of protozoal (Toxoplasma gondii) purine nucleoside phosphorylase

Benzimidazole-4,7-diones derivatives substituted at 1- and/or 2-position have been synthetized and tested as inhibitors of purine nucleoside phosphorylase (PNP), isolated from two strains of Toxoplasma gondii (RH and ME 49). They were identified as inhibi